House Health Policy Moves Oral Chemo Parity Legislation
Update: May 8-19, 2023
On May 11, 2023, the first testimony-only hearing was held on HB 4071, a bill that would prohibit health insurers from applying financial requirements that are more restrictive on oral chemotherapies than they do for IV chemotherapies. Stakeholders including the Michigan Society of Hematology and Oncology, the American Cancer Society, the Michigan State Medical Society, and Leukemia and Lymphoma Society supported the legislation’s passage and urged the committee to take swift action.
The bill sponsor, Representative Samantha Steckloff [D- Farmington Hills] gave the most powerful testimony, as hers was personal. Representative Steckloff is a breast cancer survivor and champion of oral chemotherapy parity as she herself must take an oral chemotherapy drug. A week after the first testimony-only hearing, House bill 4071 was voted out of the House Health Policy Committee by a vote of 14-3, and now awaits action on the House floor.